Information Provided By: 
Fly News Breaks for July 28, 2017
NLNK, INCY
Jul 28, 2017 | 08:23 EDT
SunTrust analyst PEter Lawson says that the failure of AstraZeneca's (AZN) PD-L1/CTLA4 combo to hit its progression free survival primary endpoint is positive for Incyte (INCY) and NewLink (NLNK0. The analyst says that the failure "relives a competitive concern" for the companies. He keeps a $145 price target and a Buy rating on Incyte.
News For INCY;NLNK From the Last 2 Days
There are no results for your query INCY;NLNK
